Abstract:From December 2022 to January 2023, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections caused by BA.5 and BF.7 subvariants of B.1.1.529 (Omicron) swept across mainland China. It is crucial to estimate the protective effect of the neutralizing antibodies generated by such mass infections against the next potential SARS-CoV-2 reinfection wave, especially if driven by CH.1.1 or XBB.1.5. Previously, we recruited and continuously followed a cohort of individuals that experienced Omicron BA.1, BA.2, and BA.5 breakthrough infections, as well as a control cohort with no history of SARS-CoV-2 infection. In the previously uninfected cohort, the total symptomatic infection rate surveyed during the outbreak was 91.6%, while the symptomatic reinfection rate was 32.9%, 10.5%, and 2.8% among individuals with prior Omicron BA.1, BA.2 and BA.5 infection, respectively, with median intervals between infections of 335, 225 and 94 days. Pseudovirus neutralization assays were performed in plasma samples collected from previously Omicron BA.1-infected individuals approximately 3 months before the outbreak. Results indicate a robust correlation between the plasma neutralizing antibody titers and the protective effect against symptomatic reinfection. The geometric mean of the 50% neutralizing titers (NT50) against D614G, BA.5, and BF.7 were 2.0, 2.5, and 2.3-fold higher in individuals without symptomatic reinfection than in those with symptomatic reinfection ( p < 0.01). Low plasma neutralizing antibody titer (below the geometric mean of NT50) was associated with an enhanced cumulative risk of symptomatic reinfection, with a hazard ratio (HR) of 23.55 (95% CI: 9.23-60.06) against BF.7 subvariant. Importantly, neutralizing antibodies titers post one month after BF.7/BA.5 breakthrough infections against CH.1.1 and XBB.1.5 are similar to that against BF.7 from individuals with prior BA.1 infection while not experiencing a symptomatic BF.7/BA.5 reinfection (plasma collected 3 months before the outbreak), suggesting that the humoral immunity generated by the current BF.7/BA.5 breakthrough infection may provide protection against CH.1.1 and XBB.1.5 symptomatic reinfection wave for 4 months. Of note, the higher hACE2 binding of XBB.1.5 may reduce the protection period since the potential increase of infectivity. ### Competing Interest Statement Y.C. are co-founders of Singlomics Biopharmaceuticals and inventors of patents associated with SARS-CoV-2 neutralizing antibodies. All other authors declare no competing interests.

COVID-19 reinfection in the presence of neutralizing antibodies

Reinfection with two genetically distinct SARS‐CoV‐2 viruses within 19 days

COVID-19 neutralizing antibodies predict disease severity and survival

Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR

Durability of Neutralizing Antibodies and T-cell Response Post SARS-CoV-2 Infection

The serological IgG and neutralizing antibody of SARS-CoV-2 omicron variant reinfection in Jiangsu Province, China

Dynamic changes of neutralizing antibody and memory T cell responses six months post Omicron XBB reinfection

COVID-19-neutralizing antibodies predict disease severity and survival

SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents

Protective Effect of Plasma Neutralization from Prior SARS-CoV-2 Omicron Infection Against BA.5 Subvariant Symptomatic Reinfection

Longitudinal neutralizing antibody responses after SARS-CoV-2 infection: A convalescent cohort study in Taiwan

Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection

Neutralizing Antibody-Mediated Protection from Prior Delta Variant Infection Against Omicron BA.5 Sub-Lineage Reinfection One Year Later: A Prospective Cohort Study

A Follow-Up Study on the Recovery and Reinfection of Omicron COVID-19 Patients in Shanghai, China.

Changes in Serum Neutralizing Antibodies Levels During Convalescence of COVID-19 Patients

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study

Enhanced immunity against SARS-CoV-2 in returning Chinese individuals

Immune features of COVID-19 convalescent individuals revealed by a single-cell RNA sequencing

Neutralization Against SARS-CoV-2 Delta/Omicron Variants and B Cell Response after Inactivated Vaccination among COVID-19 Convalescents

Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection